Roche claims key win in the $12B ear­ly-stage check­point race

Roche has staked a toe­hold in the race to push check­point ther­a­pies in­to ear­li­er and ear­li­er stages of can­cer.

The Swiss phar­ma an­nounced Mon­day that, in a Phase III tri­al of ear­ly-stage lung can­cer pa­tients, those who re­ceived the PD-1 block­er Tecen­triq lived longer with­out their dis­ease re­turn­ing than pa­tients who re­ceived chemother­a­py did. Known as IM­pow­er010, the study looked at non-small cell lung can­cer pa­tients who had al­ready un­der­gone surgery to re­move their tu­mor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER